Novartis announced acquisitions and license moves to bolster its PI3Kα oncology portfolio, agreeing to acquire Pikavation and to pay up to $3 billion and separately committing billions to Synnovation’s PI3Kα programs. Company statements said the deals center on SNV4818, a pan‑mutant selective PI3Kα inhibitor in early clinical development for HR+/HER2‑ metastatic breast cancer and other solid tumors. Novartis framed the transactions as precision‑medicine plays designed to improve tolerability versus older PI3Kα inhibitors by selectively targeting mutant enzymes and enabling combination use with endocrine and CDK inhibitors. External commentary and company releases noted the strategic intent: accelerate a next‑generation PI3Kα program into later‑stage testing and broaden Novartis’s breast‑cancer regimen options.